In 187 Chinese adults with moderate-to-severe asthma, MG-K10 (anti-IL-4Rα antibody) 300 mg every 2 or 4 weeks improved prebronchodilator FEV1 at week 12 versus placebo (+0.35 L and +0.30 L, both p<0.0001); adverse events were similar across groups.
RCTn = 187
Xian et al. Phase Ib/II Study of Preliminary Efficacy, Safety and Pharmacodynamics of MG-K10, a Humanised Monoclonal Antibody Targeting IL-4Rα, in Adult Chinese Patients With Asthma